Overview

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind Multi-centre Trial (RAPID-I)

Status:
Suspended
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.
Phase:
Phase 2
Details
Lead Sponsor:
Professor Robert Sutton
Collaborators:
Bangor University
Clinical Trials Research Centre
Liverpool Clinical Trials Centre
Liverpool University Hospitals NHS Foundation Trust
Medical Research Council
Merck Sharp & Dohme Corp.
National Institute for Health Research, United Kingdom
Royal Liverpool and Broadgreen University Hospitals NHS Trust
University of Liverpool
Treatments:
Infliximab